CVC Fund VI acquires Teva’s international women’s health assets
CVC Capital Partners’ CVC Fund VI has agreed to acquire Teva Pharmaceutical Industries Ltd’s (Teva) international (non-US), women’s health assets. The transaction covers products sold in over 50 countries globally, for a cash value of USD703 million. Headquartered in Israel, Teva is one of the world’s largest generic medicines producers,

